Search 

Strategic collaboration

2014

BalinBac has a lead clinical stage drug (phase 2/3) repurposed candidate, BB-708, with validated COVID-19 suppressing antiviral activity utilizing multiple recognized mechanisms of action. This SARS-CoV-2 activity has been demonstrated in a number of labs at a drugable micromolar level in human lung cell NHBE and Calu-3 cell line viral neutralization assays. BB-708 is a drug product in a unique inhaled drug delivery system that will stop viral replication of SARS-CoV-2. BalinBac’s multiple MOA anti-coronavirus drugs and inhaled delivery system provides a platform for repurposed therapeutics that will now have 20-year composition of matter patents as NCEs through BalinBac’s proprietary medicinal chemistry. This platform will be extended to other therapeutic areas after addressing the huge unmet need of the COVID-19 pandemic. We are seeking research collaboration and option agreements with big pharma and generic companies and are raising super-angel money to finance some small contributing studies relating to the formulation and for some general operating administrative expenses. We will be delivering the drugs to outpatients via electronic cigarettes in free base form and after this program enters the clinic will be developing a new device for hospital inpatient administration. We would be happy to talk to you about collaboration agreements and early investment.

Primary care products

Looking for potential collaboration and/or investment opportunities for technology platforms in innovation therapeutics